X

Trial Profile

Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vatiquinone (Primary)
Indications Friedreich's ataxia
Focus Therapeutic Use
Sponsors BioElectronics Corporation; Edison Pharmaceuticals; PTC Therapeutics

Most Recent Events

28 Apr 2017 Primary endpoint of Visual Function has not been met, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.
28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
18 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com